tezosentan has been researched along with avosentan in 2 studies
| Studies (tezosentan) | Trials (tezosentan) | Recent Studies (post-2010) (tezosentan) | Studies (avosentan) | Trials (avosentan) | Recent Studies (post-2010) (avosentan) |
|---|---|---|---|---|---|
| 157 | 29 | 33 | 29 | 10 | 15 |
| Protein | Taxonomy | tezosentan (IC50) | avosentan (IC50) |
|---|---|---|---|
| Endothelin receptor type B | Homo sapiens (human) | 0.9 | |
| Endothelin-1 receptor | Homo sapiens (human) | 0.0023 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bolli, MH; Boss, C; Gatfield, J | 1 |
| Cheng, G; Li, B; Li, Y; Liu, D; Lu, S; Xiao, J; Yuan, W; Zhao, Z | 1 |
2 review(s) available for tezosentan and avosentan
| Article | Year |
|---|---|
From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective.
Topics: Bosentan; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Humans; Molecular Structure; Pyrimidines; Receptors, Endothelin; Structure-Activity Relationship; Sulfonamides | 2016 |
Endothelin-receptor antagonist can reduce blood pressure in patients with hypertension: a meta-analysis.
Topics: Antihypertensive Agents; Atrasentan; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Bosentan; Endothelin Receptor Antagonists; Humans; Hypertension; Middle Aged; Models, Statistical; Phenylpropionates; Pyridines; Pyrimidines; Pyrrolidines; Randomized Controlled Trials as Topic; Sulfonamides; Survival Analysis; Tetrazoles | 2017 |